The article discusses the impact of chemotherapy-induced myelosuppression on patients' quality of life (QoL) and reviews current and future management strategies. Chemotherapy can cause myelosuppression, leading to neutropenia, anemia, and thrombocytopenia, which negatively affect patients' daily functioning and well-being. Traditional interventions such as granulocyte colony-stimulating factors (G-CSF), erythropoiesis-stimulating agents (ESAs), and blood transfusions have limitations and can cause additional side effects. Trilaciclib, approved for reducing myelosuppression in extensive-stage small cell lung cancer, has shown promise in improving QoL by reducing the duration and severity of neutropenia, anemia, and thrombocytopenia. Other investigational agents, such as plinabulin and roxadustat, are also under development and show encouraging results. The article highlights the need for proactive management strategies to improve QoL and reduce the burden of myelosuppression on patients.The article discusses the impact of chemotherapy-induced myelosuppression on patients' quality of life (QoL) and reviews current and future management strategies. Chemotherapy can cause myelosuppression, leading to neutropenia, anemia, and thrombocytopenia, which negatively affect patients' daily functioning and well-being. Traditional interventions such as granulocyte colony-stimulating factors (G-CSF), erythropoiesis-stimulating agents (ESAs), and blood transfusions have limitations and can cause additional side effects. Trilaciclib, approved for reducing myelosuppression in extensive-stage small cell lung cancer, has shown promise in improving QoL by reducing the duration and severity of neutropenia, anemia, and thrombocytopenia. Other investigational agents, such as plinabulin and roxadustat, are also under development and show encouraging results. The article highlights the need for proactive management strategies to improve QoL and reduce the burden of myelosuppression on patients.